<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article193</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/ProMISe" style="display:block; margin-bottom:10px;">ProMISe Original</a></li>
<h2><strong>ProMISe</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>
<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does protocolized hemodynamic management (early, goal-directed therapy [EGDT]) in early septic shock improve outcomes compared with usual care?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In adults with early signs of septic shock, EGDT including intravenous antibiotics and adequate fluid resuscitation does not lead to improved outcomes compared with usual resuscitation care.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Pragmatic, open, multicenter, parallel-group, randomized, controlled trial<br/>
- N=1,260 patients with early septic shock<br/>
- Intervention: EGDT (n=630)<br/>
- Control: Usual resuscitation care (n=630)<br/>
- Setting: 56 hospitals in England<br/>
- Enrollment period: February 16, 2011, to July 24, 2014<br/>
- Primary outcome: All-cause mortality at 90 days<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria:<br/>
- Adults (≥18 years)<br/>
- Presentation within 6 hours after emergency department visit<br/>
- Infection, systemic inflammatory response syndrome criteria, and hypotension or hyperlactatemia<br/>
<br/>
Exclusion Criteria:<br/>
- Criteria not mentioned in the provided abstract<br/>
<br/>
Baseline Characteristics<br/>
- Similar in both groups<br/>
- Refractory hypotension criteria met in approximately 55% of patients in both groups<br/>
- Hyperlactatemia criteria met in 65.4% in EGDT and 63.7% in usual care<br/>
- Mean first ScvO2 was 70±12%<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- EGDT group: 6-hour resuscitation protocol guided by central venous pressure, mean arterial pressure, central venous oxygen saturation<br/>
- Usual care group: Treatment decisions made by the treating clinicians, no protocolized resuscitation<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary Outcome: No significant difference in 90-day all-cause mortality (EGDT 29.5% vs. usual care 29.2%, RR 1.01, 95% CI 0.85 to 1.20, P=0.90)<br/>
- Increased treatment intensity in the EGDT group, including use of intravenous fluids, vasoactive drugs, and red-cell transfusions<br/>
- No differences in health-related quality of life or rates of serious adverse events<br/>
- Costs were higher on average in the EGDT group<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The intervention could not be blinded.<br/>
- Only one-third of eligible patients were enrolled.<br/>
- Mortality rates were lower than anticipated.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Funded by the United Kingdom National Institute for Health Research Health Technology Assessment Programme<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- ProCESS and ARISE trials, which also assessed EGDT in septic shock.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
